Role of different non-coding RNAs as ovarian cancer biomarkers

Background Among many gynecological malignancies ovarian cancer is the most prominent and leading cause of female mortality worldwide. Despite extensive research, the underlying cause of disease progression and pathology is still unknown. In the progression of ovarian cancer different non-coding RNAs have been recognized as important regulators. The biology of ovarian cancer which includes cancer initiation, progression, and dissemination is found to be regulated by different ncRNA. Clinically ncRNA shows high prognostic and diagnostic importance. Results In this review, we prioritize the role of different non-coding RNA and their perspective in diagnosis as potential biomarkers in the case of ovarian cancer. Summary of some of the few miRNAs involved in epithelial ovarian cancer their expression and clinical features are being provided in the table. Also, in cancer cell proliferation, apoptosis, invasion, and migration abnormal expression of piRNAs are emerging as a crucial regulator hence the role of few piRNAs is being given. Both tRFs and tiRNAs play important roles in tumorigenesis and are promising diagnostic biomarkers and therapeutic targets for cancer. lncRNA has shown a leading role in malignant transformation and potential therapeutic value in ovarian cancer therapy. Conclusions Hence in this review we demonstrated the role of different ncRNA that play an important role in serving strong potential as a therapeutic approach for the treatment of ovarian cancer.

Automated summary

This review highlights the role of different non-coding RNAs as potential biomarkers in the diagnosis of ovarian cancer. It summarizes the expression and clinical features of a few miRNAs involved in epithelial ovarian cancer. Additionally, the abnormal expression of piRNAs has been found to play a crucial regulatory role in cancer cell proliferation, apoptosis, invasion, and migration, while tRFs and tiRNAs hold promise as diagnostic biomarkers and therapeutic targets for cancer.